antifungal antibiotics

Summary

Summary: Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases.

Top Publications

  1. pmc In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts
    F Sabatelli
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Antimicrob Agents Chemother 50:2009-15. 2006
  2. pmc Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program
    M A Pfaller
    Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA
    Antimicrob Agents Chemother 46:1032-7. 2002
  3. pmc Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
    Manuel Cuenca-Estrella
    Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda Madrid, Spain
    Antimicrob Agents Chemother 50:917-21. 2006
  4. pmc Use of PCR-targeted mutagenesis to disrupt production of fusaricidin-type antifungal antibiotics in Paenibacillus polymyxa
    Jingru Li
    Department of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
    Appl Environ Microbiol 73:3480-9. 2007
  5. ncbi Paracoccidioides brasiliensis, paracoccidioidomycosis, and antifungal antibiotics
    G Visbal
    Center of Chemistry, Instituto Venezolano de Investigaciones Cientificas IVIC, P O Box 21827, Caracas, Venezuela
    Curr Drug Targets Infect Disord 5:211-26. 2005
  6. ncbi The 2.2 A structure of the rRNA methyltransferase ErmC' and its complexes with cofactor and cofactor analogs: implications for the reaction mechanism
    G Schluckebier
    Abbott Laboratories, D46Y AP 10, 100 Abbott Park Road, Abbott Park, IL, 60064, USA
    J Mol Biol 289:277-91. 1999
  7. ncbi Antifungal antibiotics
    M Gupte
    Food and Fermentation Technology Division, University Department of Chemical Technology, Matunga, Mumbai, India
    Appl Microbiol Biotechnol 58:46-57. 2002
  8. ncbi Paenibacillus polymyxa produces fusaricidin-type antifungal antibiotics active against Leptosphaeria maculans, the causative agent of blackleg disease of canola
    Perrin H Beatty
    Department of Biological Sciences, University of Alberta, Edmonton, Canada
    Can J Microbiol 48:159-69. 2002
  9. ncbi Mutational analysis of Encephalitozoon cuniculi mRNA cap (guanine-N7) methyltransferase, structure of the enzyme bound to sinefungin, and evidence that cap methyltransferase is the target of sinefungin's antifungal activity
    Sushuang Zheng
    Molecular Biology Program, Sloan Kettering Institute, Weill College of Medicine of Cornell University, New York, New York 10021, USA
    J Biol Chem 281:35904-13. 2006
  10. ncbi Modulatory effect of cAMP on fungal ergosterol level and inhibitory activity of azole drugs
    S Sardari
    Biomedical Sciences, Fogarty Hall, 41 Lower College Road, University of Rhode Island, Kingston, RI 02881, USA
    Can J Microbiol 49:344-9. 2003

Research Grants

Detail Information

Publications213 found, 100 shown here

  1. pmc In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts
    F Sabatelli
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Antimicrob Agents Chemother 50:2009-15. 2006
    ..Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was frequently more active than other azoles and amphotericin B...
  2. pmc Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program
    M A Pfaller
    Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA
    Antimicrob Agents Chemother 46:1032-7. 2002
    ..Surveillance efforts should be expanded in order to monitor the spectrum of filamentous fungal pathogens and their in vitro susceptibility as these new antifungal agents are introduced into clinical use...
  3. pmc Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
    Manuel Cuenca-Estrella
    Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda Madrid, Spain
    Antimicrob Agents Chemother 50:917-21. 2006
    ..Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species...
  4. pmc Use of PCR-targeted mutagenesis to disrupt production of fusaricidin-type antifungal antibiotics in Paenibacillus polymyxa
    Jingru Li
    Department of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada
    Appl Environ Microbiol 73:3480-9. 2007
    ..polymyxa by intergeneric conjugation. Targeted disruption of fusA led to the complete loss of antifungal activity against L. maculans, suggesting that fusA plays an essential role in the nonribosomal synthesis of fusaricidins...
  5. ncbi Paracoccidioides brasiliensis, paracoccidioidomycosis, and antifungal antibiotics
    G Visbal
    Center of Chemistry, Instituto Venezolano de Investigaciones Cientificas IVIC, P O Box 21827, Caracas, Venezuela
    Curr Drug Targets Infect Disord 5:211-26. 2005
    ....
  6. ncbi The 2.2 A structure of the rRNA methyltransferase ErmC' and its complexes with cofactor and cofactor analogs: implications for the reaction mechanism
    G Schluckebier
    Abbott Laboratories, D46Y AP 10, 100 Abbott Park Road, Abbott Park, IL, 60064, USA
    J Mol Biol 289:277-91. 1999
    ..A model for the transition-state based on the atomic details of the active site is consistent with a one-step methyl-transfer mechanism and might serve as a first step towards the design of potent Erm inhibitors...
  7. ncbi Antifungal antibiotics
    M Gupte
    Food and Fermentation Technology Division, University Department of Chemical Technology, Matunga, Mumbai, India
    Appl Microbiol Biotechnol 58:46-57. 2002
    ..The present article reviews the current types of antifungal infections, the current scenario of antifungal antibiotics, and the need and approaches to search for newer antifungal antibiotics and antifungal drug targets.
  8. ncbi Paenibacillus polymyxa produces fusaricidin-type antifungal antibiotics active against Leptosphaeria maculans, the causative agent of blackleg disease of canola
    Perrin H Beatty
    Department of Biological Sciences, University of Alberta, Edmonton, Canada
    Can J Microbiol 48:159-69. 2002
    ..These compounds are therefore members of the fusaricidin group of cyclic depsipeptides...
  9. ncbi Mutational analysis of Encephalitozoon cuniculi mRNA cap (guanine-N7) methyltransferase, structure of the enzyme bound to sinefungin, and evidence that cap methyltransferase is the target of sinefungin's antifungal activity
    Sushuang Zheng
    Molecular Biology Program, Sloan Kettering Institute, Weill College of Medicine of Cornell University, New York, New York 10021, USA
    J Biol Chem 281:35904-13. 2006
    ..We find that the sensitivity of Saccharomyces cerevisiae to growth inhibition by sinefungin is diminished when Abd1 is overexpressed. These results highlight cap methylation as a principal target of the antifungal activity of sinefungin...
  10. ncbi Modulatory effect of cAMP on fungal ergosterol level and inhibitory activity of azole drugs
    S Sardari
    Biomedical Sciences, Fogarty Hall, 41 Lower College Road, University of Rhode Island, Kingston, RI 02881, USA
    Can J Microbiol 49:344-9. 2003
    ..The possible significance of this interaction includes potentiation of antifungal activity of drugs by manipulating the cAMP level...
  11. ncbi Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp
    Estrella Martin-Mazuelos
    Servicio de Microbiologia, Hospital Universitario de Valme, Sevilla, Spain
    J Antimicrob Chemother 52:365-70. 2003
    ....
  12. pmc Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis
    William R Kirkpatrick
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 7881, San Antonio, TX 78229 3900, USA
    Antimicrob Agents Chemother 46:2564-8. 2002
    ..The combinations of CAS plus VRC were highly effective in this model and should be further evaluated for use against invasive aspergillosis...
  13. pmc Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole
    Rama Ramani
    Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York 12208, USA
    Antimicrob Agents Chemother 47:3627-9. 2003
    ..FC results after 4 h correlated well with MICs obtained by the NCCLS M38-A method; voriconazole exhibited fungicidal activity, albeit to a lesser extent than amphotericin B, but to a greater extent than itraconazole...
  14. ncbi [The future of antifungal agents]
    Shigefumi Maesaki
    Rinsho Ketsueki 48:26-35. 2007
  15. pmc Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factor
    Alieke G Vonk
    Department of Medicine, Division of General Internal Medicine Department of Pathology, University Medical Center Nijmegen, The Netherlands
    Antimicrob Agents Chemother 47:3688-93. 2003
    ..In contrast, addition of rmG-CSF therapy to antifungal treatment might further enhance the beneficial effect of the antifungal agent...
  16. ncbi Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent
    Tamara Koss
    Department of Dermatology, Columbia Presbyterian Medical Center, New York, New York, USA
    J Am Acad Dermatol 46:945-7. 2002
    ..Caspofungin shows great promise in the treatment of invasive aspergillosis...
  17. ncbi Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents
    Anne Favel
    Laboratoire de Botanique, Cryptogamie et Biologie Cellulaire, Faculte de Pharmacie, 13385 Marseille, France
    J Antimicrob Chemother 53:526-9. 2004
    ..The aim of the present study was to expand the MIC database for Candida lusitaniae in order to further determine its antifungal susceptibility pattern...
  18. pmc Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits
    Ruta Petraitiene
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:1188-96. 2004
    ..Intravenously administered ravuconazole lysine phosphoester showed dose-dependent efficacy and an excellent safety profile for the treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits...
  19. pmc In vitro activity of anidulafungin against selected clinically important mold isolates
    Zekaver Odabasi
    Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Houston Medical School, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 48:1912-5. 2004
    ....
  20. pmc In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models
    D T A Te Dorsthorst
    Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:2007-13. 2004
    ..However, the correlation of these results with clinical outcome remains difficult and needs to be further investigated...
  21. pmc Effects of voriconazole on Cryptococcus neoformans
    David van Duin
    Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA
    Antimicrob Agents Chemother 48:2014-20. 2004
    ..The high activity of voriconazole against both melanized and nonmelanized cells results suggest that voriconazole may be a particularly valuable drug for cryptococcosis...
  22. ncbi Impact of lysozyme and lactoferrin on oral Candida isolates exposed to polyene antimycotics and fluconazole
    S Anil
    Oral Bio Sciences, Faculty of Dentistry, University of Hong Kong
    Oral Dis 8:199-206. 2002
    ....
  23. ncbi Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes
    Clarissa K L Ng
    School of Chemistry, The University of Sydney, 2006 NSW, Australia
    Bioorg Med Chem 15:3422-9. 2007
    ..However, shortening or removing the alkyl chains attached to the amino groups had little effect on antifungal activity and significantly reduced haemolytic activity. Only octenidine was a strong inhibitor of fungal phospholipase B1...
  24. ncbi Fungal infections in neonates: update on prevention and treatment
    D A Kaufman
    Department of Pediatrics, University of Virginia School of Medicine Charlottesville, VA 22908, USA
    Minerva Ginecol 59:311-29. 2007
    ..Liposomal amphotericin formulations and echinochandins are currently being studied in neonates. Prevention for high risk patients is now feasible with fluconazole prophylaxis...
  25. ncbi [Investigation of the activity of the preparation cerbiden against Candida spp]
    N P Hladun
    Taras Shevchenko Kyiv National University, 2 12 Acad Glushkov Avenue, Kyiv, 03022, Ukraine
    Mikrobiol Z 64:57-61. 2002
    ..High cerbiden activity against clinical and museum strains of Candida albicans, C. tropicalis, C. krusei, C. parapsilosis, C. guilliermondii, sensitive and resistant to nystatin, amphotericin B and clotrimazole was determined...
  26. ncbi Caspofungin versus amphotericin B for invasive candidiasis
    Adam L Brown
    N Engl J Med 348:1287-8; author reply 1287-8. 2003
  27. ncbi Systemic mycoses in the immunocompromised host: an update in antifungal therapy
    D P Kontoyiannis
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Hosp Infect 53:243-58. 2003
    ..Ongoing and future studies will determine their exact role in the management of different mycoses. The acceleration of antifungal drug discovery offers promise for the management of these difficult to treat opportunistic infections...
  28. ncbi Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B
    P A Warn
    School of Medicine, University of Manchester, Manchester, UK
    J Antimicrob Chemother 51:913-9. 2003
    ..terreus infection. No treatment regime was able to totally clear the liver or kidneys in either model. The data indicate that FK463 may have a clinical role in the treatment of life-threatening invasive aspergillosis...
  29. pmc Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology
    Joseph Meletiadis
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:3329-37. 2007
    ....
  30. pmc In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents
    Nikolaos G Almyroudis
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Antimicrob Agents Chemother 51:2587-90. 2007
    ..The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae...
  31. ncbi In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi
    Guillermo Garcia-Effron
    Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Madrid, Spain
    J Antimicrob Chemother 53:1086-9. 2004
    ..The activity in vitro of terbinafine against 442 clinical isolates of several species of filamentous fungi was analysed...
  32. ncbi Effects of melanin upon susceptibility of Cryptococcus to antifungals
    Reiko Ikeda
    Department of Microbiology, Meiji Pharmaceutical University, Kiyose, Tokyo 204 8588, Japan
    Microbiol Immunol 47:271-7. 2003
    ..Fluconazole, in contrast, was not removed from solution by melanin. This suggests that neoformans cryptococcal melanin deposited amphotericin B in the cell wall binds, reducing its effective concentrations...
  33. pmc Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy
    Albrecht Serfling
    Faculty of Agriculture, Institute of Agricultural and Nutritional Sciences, Phytopathology and Plant Protection, Martin Luther University Halle Wittenberg, D 06099, Halle Saale, Germany
    Antimicrob Agents Chemother 51:3672-6. 2007
    ..Azole-adapted strains were less sensitive to all azoles tested but showed increased sensitivity to caspofungin, amphotericin B, and nystatin. Viability staining and infection assays with excised human skin confirmed these data...
  34. ncbi Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques
    E M P Moraes
    Department of Microbiology, Institute of Biological Sciences, Minas Gerais, Brazil
    Mycoses 46:164-8. 2003
    ..was applied, a fact possibly related to the greater difficulty for treatment of the disease caused by this fungal variety...
  35. pmc Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation
    W Lamar Smith
    Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, USA
    Antimicrob Agents Chemother 46:3532-9. 2002
    ..This most likely explains the inhibition of azole and terbinafine trailing by TSA and, more generally, provides evidence that trailing is mediated by upregulation of target enzymes and multidrug transporters...
  36. pmc Activity of posaconazole in treatment of experimental disseminated zygomycosis
    Eric Dannaoui
    Department of Medical Microbiology, University Medical Center, St Radboud, 6500 HB Nijmegen, The Netherlands
    Antimicrob Agents Chemother 47:3647-50. 2003
    ..Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera. Posaconazole had a clear dose-response effect against R. microsporus...
  37. pmc Molecular mechanisms of itraconazole resistance in Candida dubliniensis
    Emmanuelle Pinjon
    Microbiology Research Unit, Department of Oral Medicine and Oral Pathology, School of Dental Science, Trinity College, University of Dublin, Dublin 2, Republic of Ireland
    Antimicrob Agents Chemother 47:2424-37. 2003
    ..dubliniensis derivatives. However, the mechanism(s) of itraconazole resistance in the remaining seventh derivative has yet to be determined...
  38. ncbi New drugs, old drugs - dear drugs, cheap drugs
    Bernard Hirschel
    Swiss Med Wkly 132:301-2. 2002
  39. ncbi In vivo characterization of A-192411: a novel fungicidal lipopeptide (II)
    Jonathan A Meulbroek
    Infectious Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 13:495-7. 2003
    ..A-192411 also slightly prolonged the survival of immunocompromised mice infected systemically with Aspergillus fumigatus...
  40. ncbi Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans
    Katherine S Barker
    Department of Pharmacy, College of Pharmacy, University of Tennessee Health Science Center, Memphis, USA
    J Antimicrob Chemother 54:376-85. 2004
    ..The aim of this study was to identify changes in the gene expression profile of Candida albicans associated with the acquisition of experimentally induced resistance to amphotericin B and fluconazole...
  41. pmc Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 50:3695-700. 2006
    ..This pharmacokinetic-pharmacodynamic picture of anidulafungin persistence in tissues and the resultant persistent fungal decline should be exploited to improve the efficacy of anidulafungin therapy for candidemia...
  42. ncbi Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease
    S Anil
    Oral Bio-Sciences, Faculty of Dentistry, University of Hong Kong
    J Oral Pathol Med 30:481-8. 2001
    ..albicans species in the face of antifungal therapy for oropharyngeal candidiasis...
  43. pmc Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
    G Ramage
    Department of Microbiology, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, Texas 78245, USA
    Antimicrob Agents Chemother 45:2475-9. 2001
    ....
  44. pmc In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients
    William J Steinbach
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Antimicrob Agents Chemother 48:4922-5. 2004
    ..We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients...
  45. ncbi Antifungal resistance: the clinical front
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 18:15-22. 2004
    ..Caspofungin and voriconazole show good activity against most Candida species and may be good alternatives for patients with Candida glabrata and Candida krusei infections and for those with relapsing infections...
  46. ncbi Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice
    M Alam Khan
    Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India
    J Drug Target 12:425-33. 2004
    ..Efficacy of the treatment was evaluated on the basis of survival of the animals as well as fungal load in systemic circulation and various organs viz. liver, kidney, spleen and lungs of the treated animals...
  47. ncbi Breakthrough candida Infection in a preterm infant with congenital cutaneous Candida albicans infection
    Amos Adler
    Department of Neonatology, Meir Medical Center, Kfar Saba 95847, Israel
    Am J Perinatol 22:169-72. 2005
    ..We discuss the pathogenesis of breakthrough infections, and the relevance of antifungal resistance and sensitivities testing...
  48. ncbi Antifungal treatment in pediatric patients
    Theoklis E Zaoutis
    Department of Pediatrics, Division of Infectious Diseases, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Drug Resist Updat 8:235-45. 2005
    ....
  49. pmc In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata
    Francesco Barchiesi
    Istituo di Malattie Infettive e Medicina Pubblica, Universita Politecnica delle Marche, Azienda Ospedaliera Umberto I degrees, Via Conca, 60020 Torrette di Ancona, Ancona, Italy
    Antimicrob Agents Chemother 48:3317-22. 2004
    ..Further studies are warranted to elucidate the potential beneficial effects of such combination regimens in vivo...
  50. pmc Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates
    D T A Te Dorsthorst
    Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:3147-50. 2004
    ..0 than at pH 7.0. The poor correlation between in vitro results and clinical outcome could be due to a difference in pH between the in vitro susceptibility test and at the site of infection...
  51. ncbi [Antifungal susceptibility of clinically isolated Candida albicans by broth microdilution method]
    T Yamazumi
    Department of Clinical Pathology, Kinki University School of Medicine
    Kansenshogaku Zasshi 72:813-9. 1998
    ..There were two flucytosine resistant strains. The MICs of amphotericin B were tightly clustered and resistant strain were not observed...
  52. pmc Caspofungin in combination with amphotericin B against Candida parapsilosis
    Francesco Barchiesi
    Istituto di Malattie Infettive e Medicina Pubblica, Universita Politecnica delle Marche, Azienda, Ospedaliero Universitaria, Ospedali Riuniti Umberto I Lancisi Salesi, Via Conca, 60020 Torrette, Ancona, Italy
    Antimicrob Agents Chemother 51:941-5. 2007
    ..Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis...
  53. pmc Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis
    Carolina Serena
    Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, Carrer Sant Llorenç, Reus, Spain
    Antimicrob Agents Chemother 50:2240-3. 2006
    ..VRC was more effective than amphotericin B in prolonging survival and reducing tissue burden. The best results were obtained with VRC at 10 mg/kg of body weight/day...
  54. ncbi Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002
    Borann Sar
    Laboratory of Medical Microbiology, Unit of Clinical Testing, Institut Pasteur du Cambodge, 5 Boulevard Monivong, BP 983, Phnom Penh, Cambodia
    J Antimicrob Chemother 54:563-5. 2004
    ..Hospitalized patients were given amphotericin B for initial therapy followed by fluconazole for maintenance therapy. The antifungal drug susceptibility of Cryptococcus neoformans isolated from cerebrospinal fluid (CSF) was determined...
  55. ncbi Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience
    Cornelia Lass-Flörl
    Department of Hygiene, Microbiology and Social Medicine, Medical University of Innsbruck, Innsbruck, Austria
    Br J Haematol 131:201-7. 2005
    ..terreus causes systemic infections of endemic character in Tyrol, Austria. The onset of A. terreus infection depends not on the degree of immunosuppression but on environmental Aspergillus spp. exposure...
  56. ncbi In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole
    A Gomez-Lopez
    Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Madrid, Spain
    J Antimicrob Chemother 48:919-21. 2001
    ..The species of Zygomycota tested were resistant in vitro to flucytosine, itraconazole and voriconazole. Amphotericin B showed the best activity against most of the strains evaluated...
  57. ncbi A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans
    Elias K Manavathu
    Division of Infectious Diseases, Department of Internal Medicine, 427 Lande Building, Wayne State University, 550 E Canfield, Detroit, MI 48201, USA
    J Antimicrob Chemother 53:386-9. 2004
    ..To study the post-antifungal effect (PAFE) of antifungal drugs on Aspergillus fumigatus by a radiometric assay and compare the results with those obtained for Candida albicans...
  58. pmc Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate
    J C Bowman
    Department of Human and Animal Infectious Disease Research, Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA
    Antimicrob Agents Chemother 45:3474-81. 2001
    ..Because of its much larger dynamic range, the qPCR assay is superior to traditional CFU determination for monitoring the progression of disseminated aspergillosis and evaluating the activity of antifungal antibiotics against A. fumigatus.
  59. ncbi Suppression of maize root diseases caused by Macrophomina phaseolina, Fusarium moniliforme and Fusarium graminearum by plant growth promoting rhizobacteria
    K K Pal
    Division of Microbiology, Indian Agricultural Research Institute, New Delhi
    Microbiol Res 156:209-23. 2001
    ..Pseudomonas sp. EM85 produced antifungal antibiotics (Afa+), siderophore (Sid+), HCN (HCN+) and fluorescent pigments (Flu+) besides exhibiting plant growth ..
  60. ncbi Biosynthetic engineering of polyene macrolides towards generation of improved antifungal and antiparasitic agents
    Patrick Caffrey
    School of Biomolecular and Biomedical Science and Centre for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
    Curr Top Med Chem 8:639-53. 2008
    ..They are medically important as antifungal antibiotics but their therapeutic use is limited by serious side effects...
  61. ncbi Biocontrol of avocado dematophora root rot by antagonistic Pseudomonas fluorescens PCL1606 correlates with the production of 2-hexyl 5-propyl resorcinol
    Francisco M Cazorla
    Departamento de Microbiologia, Facultad de Ciencias, Universidad de Malaga, Campus Universitario de Teatinos, S N, 29071 Malaga, Spain
    Mol Plant Microbe Interact 19:418-28. 2006
    ..fluorescens PCL1606 did not correspond to any of the major classes of antifungal antibiotics produced by Pseudomonas biocontrol strains...
  62. ncbi Antifungal characteristics of a fluorescent Pseudomonas strain involved in the biological control of Rhizoctonia solani
    K K Pal
    Division of Microbiology, Indian Agricultural Research Institute, New Delhi
    Microbiol Res 155:233-42. 2000
    ..The isolate produced HCN (HCN+), siderophore (Sid+), fluorescent pigments (Flu+) and antifungal antibiotics (Afa+)...
  63. ncbi Regulation of antibiotic production in root-colonizing Peudomonas spp. and relevance for biological control of plant disease
    Dieter Haas
    Institut de Microbiologie Fondamentale, Universite de Lausanne, CH 1015 Lausanne, Switzerland Email
    Annu Rev Phytopathol 41:117-53. 2003
    ..colonization, induction of systemic resistance in the plant, and the production of diffusible or volatile antifungal antibiotics. Evidence that these compounds are produced in situ is based on their chemical extraction from the ..
  64. ncbi Characterization of antimicrobial peptides against a US strain of the rice pathogen Rhizoctonia solani
    S Oard
    LSU AgCenter Biotechnology Laboratory, Louisiana State University, Baton Rouge, LA 70803, USA
    J Appl Microbiol 97:169-80. 2004
    ..To identify antimicrobial peptides with high lytic activity against Rhizoctonia solani strain LR172, causal agent of rice sheath blight and aerial blight of soyabeans in the US...
  65. ncbi [Diversity of neutrotolerant acidophilic Streptomycetes isolated from acidic soils in Yunnan Province]
    Chunguang Xu
    State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
    Wei Sheng Wu Xue Bao 48:421-5. 2008
    ..acitnomycetes are active in the turnover of organic matter in acid litters and soils, and are a source of antifungal antibiotics and acid-stable enzymes...
  66. ncbi Characteristics and biotechnological applications of microbial cholesterol oxidases
    Noriyuki Doukyu
    Bio Nano Electronic Research Center, Toyo University, Kujirai, Kawagoe, Saitama, Japan
    Appl Microbiol Biotechnol 83:825-37. 2009
    ..implicated in the cholesterol metabolism, the bacterial pathogenesis, and the biosynthesis of macrolide antifungal antibiotics. Cholesterol oxidase has been reported from a variety of microorganisms, mostly from actinomycetes...
  67. ncbi Sensitivity of ornithophillic fungi to some drugs
    Avni Patel
    Department of Applied Microbiology and Biotechnology, Dr Hari Singh Gour Vishwavidhyalaya, Sagar 470 003, M P, India
    Hindustan Antibiot Bull 44:49-52. 2002
    ..of Microsporum were tested by 'Spore germination' and 'Disc diffusion method' against the two well known antifungal antibiotics i.e. griseofulvin and mycostatin (polyene antibiotic)...
  68. ncbi Identification of antifungal antibiotics of Bacillus species isolated from different microhabitats using polymerase chain reaction and MALDI-TOF mass spectrometry
    Sarangi N P Athukorala
    Department of Plant Science, University of Manitoba, Winnipeg, Canada
    Can J Microbiol 55:1021-32. 2009
    ..To the best of our knowledge, this is the first report of a B. mycoides strain that carries biosynthetic genes and produces fengycin and surfactin...
  69. ncbi Biosynthesis of the polyene antifungal antibiotic nystatin in Streptomyces noursei ATCC 11455: analysis of the gene cluster and deduction of the biosynthetic pathway
    T Brautaset
    UNIGEN Center for Molecular Biology, Department of Biotechnology, Norwegian University of Science and Technology, Trondheim, N 7489, Norway
    Chem Biol 7:395-403. 2000
    ..Molecular cloning and characterization of the genes governing the nystatin biosynthesis is of considerable interest because this information can be used for the generation of new antifungal antibiotics.
  70. ncbi Genetic analysis of nystatin and amphotericin biosynthesis
    Sergey Zotchev
    Department of Biotechnology, Norwegian University of Science and Technology, Trondheim, Norway
    Methods Enzymol 459:243-58. 2009
    The polyene macrolides nystatin A1 and amphotericin B are effective but toxic antifungal antibiotics that are also active against enveloped viruses, protozoan parasites and pathogenic prion proteins...
  71. ncbi Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus
    F M Muller
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Pediatr 158:187-99. 1999
    ..broad-spectrum third generation triazoles and novel fungicidal lipopeptides of the echinocandin class of antifungal antibiotics have entered clinical trials...
  72. ncbi Selective isolation of members of the Streptomyces violaceoruber clade from soil
    Kannika Duangmal
    School of Biology, University of Newcastle, Newcastle upon Tyne, NE1 7RU, UK
    FEMS Microbiol Lett 245:321-7. 2005
    ..isolation medium, dextran-histidine-sodium chloride-mineral salts agar supplemented with antibacterial and antifungal antibiotics, also supported the growth of representatives of the S. violaceoruber clade...
  73. ncbi Antifungal antibiotics from Calcarisporium thermophilum: a new source of 15-azahomosterol derivatives
    P Chrisp
    Department of Pharmaceutical Sciences, University of Nottingham
    Z Naturforsch C 45:179-86. 1990
    ..Calcarisporium thermophilum is the second microorganism known to synthesize these unusual 15-azahomosterol derivatives...
  74. ncbi Selection for biocontrol bacteria antagonistic toward Rosellinia necatrix by enrichment of competitive avocado root tip colonizers
    Clara Pliego
    IFAPA, Centro de Churriana CICE Junta de Andalucía, Cortijo de la Cruz s n, 29140 Churriana, Malaga, Spain
    Res Microbiol 158:463-70. 2007
    ..Only one of these strains, Pseudomonas sp. AVO94, produced a compound that could be related to antifungal antibiotics. All of the ten selected strains showed twitching motility, a cell movement involved in competitive ..
  75. pmc Forest soil metagenome gene cluster involved in antifungal activity expression in Escherichia coli
    Eu Jin Chung
    Division of Applied Biology, College of Natural Resources and Life Science, Dong A University, Busan 604 714, Republic of Korea
    Appl Environ Microbiol 74:723-30. 2008
    ..Our results suggested the metagenomic approach as an alternative to search for novel antifungal antibiotics from unculturable soil bacteria...
  76. ncbi [New antifungal antibiotics, bacillopeptins and fusaricidins]
    Miyuki Kaneda
    Graduate School of Biomedical Sciences, Hiroshima University, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8551, Japan
    Yakugaku Zasshi 122:651-71. 2002
    We isolated four strains of bacteria producing antifungal antibiotics from the rhizosphere of garlic with basal rot caused by the plant pathogenic fungal strain Fusarium oxysporum...
  77. ncbi [The immune response to fungal infections]
    Piotr Kurnatowski
    Zakład Biologii i Parazytologii Lekarskiej, Uniwersytet Medyczny, Plac Hallera 1, 90 647 Łódź
    Wiad Parazytol 56:23-7. 2010
    ..the nature and function of the immune system in mycoses is necessary to enable improvements in pharmacotherapy with antifungal antibiotics and chemotherapeutics, as well as to treatments based on immunotherapy and vaccination.
  78. ncbi Cloning, sequencing, and characterization of the pradimicin biosynthetic gene cluster of Actinomadura hibisca P157-2
    Byung Chul Kim
    Division of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 136 713, Korea
    J Microbiol Biotechnol 17:830-9. 2007
    Pradimicins are potent antifungal antibiotics having an unusual dihydrobenzo[alpha]naphthacenequinone aglycone substituted with D-alanine and sugars. Pradimicins are polyketide antibiotics produced by Actinomadura hibisca P157-2...
  79. ncbi Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells
    Manabu Kawada
    Numazu Bio Medical Research Institute, Microbial Chemistry Research Center, 18 24 Miyamoto, Numazu shi, Shizuoka 410 0301, Japan
    Int J Cancer 126:810-8. 2010
    ..As a result, we have found that leucinostatins and atpenins, natural antifungal antibiotics, inhibit the growth of DU-145 cells cocultured with PrSC more strongly than that of DU-145 cells alone...
  80. ncbi Effect of liquid culture requirements on antifungal antibiotic production by Streptomyces rimosus MY02
    Jicheng Yu
    Department of Bioengineering, Dalian Nationalities University, Dalian, PR China
    Bioresour Technol 99:2087-91. 2008
    ..e. initial pH and temperature) on production of antifungal antibiotics by S. rimosus MY02 was investigated in our work...
  81. ncbi New antifungal antibiotics pradimicins FA-1 and FA-2: D-serine analogs of pradimicins A and C
    Y Sawada
    Bristol Myers Research Institute, Ltd, Tokyo Research Center, Japan
    J Antibiot (Tokyo) 43:1223-9. 1990
    ..Pradimicin FA-1 has an N-methylamino sugar and D-xylose. Pradimicin FA-2 is the des-N-methyl analog of pradimicin FA-1. The in vitro and in vivo antifungal activity of the analogs was comparable to that of pradimicin A...
  82. ncbi Isolation and characterization of two new antifungal antibiotics from a basidiomycete
    Min Chu
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey, USA
    J Antibiot (Tokyo) 56:9-15. 2003
    ..Both components were identified as glycolipids and displayed antifungal activity against Saccharomyces and Aspergillus strains...
  83. ncbi Generation of new benanomicin analogues by biotransformation using Escherichia coli expressing actinomycete cytochrome P450
    Hiroyuki Kumagai
    Microbial Chemistry Research Center, Tokyo, Japan
    J Antibiot (Tokyo) 61:394-9. 2008
    Benanomicins were found as antifungal antibiotics from the culture of an actinomycete with potent antifungal activities in vitro and in vivo...
  84. pmc Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta
    Joel T Adler
    Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin, H4 750 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Mol Cancer Ther 8:914-20. 2009
    ..Thus, there is an urgent need for new treatment modalities. Tautomycin and tautomycetin are antifungal antibiotics isolated from Streptomyces spiroverticillatus and Streptomyces griseochromogens, respectively...
  85. ncbi Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. III. Biological properties and mechanism of action
    S Kadam
    Abbott Laboratories, Abbott Park, Illinois 60064
    J Antibiot (Tokyo) 47:875-80. 1994
    ..The activity of these compounds was not dependent on inhibition of prenylation or protein synthesis. Dorrigocin A was instead found to inhibit the carboxyl methylation in K-ras transformed cells...
  86. ncbi Probiotic bacteria for prophylaxis and therapy of candidiasis
    E Balish
    University of Wisconsin Medical School, Departments of Surgery and Medical Microbiology and Immunology, Madison, WI 53706 1532, USA
    Rev Iberoam Micol 15:261-4. 1998
    ..The increased incidence of Candida infections, their increasing resistance to antifungal antibiotics and the fact that vaccines to protect against candidiasis are not yet available (and may not work in ..
  87. ncbi Biological control of soil-borne pathogens by fluorescent pseudomonads
    Dieter Haas
    Department of Fundamental Microbiology, University of Lausanne, CH 1015 Lausanne, Switzerland
    Nat Rev Microbiol 3:307-19. 2005
    ..During root colonization, these bacteria produce antifungal antibiotics, elicit induced systemic resistance in the host plant or interfere specifically with fungal pathogenicity ..
  88. ncbi Management of invasive mycoses in hematology patients: current approaches
    John R Perfect
    Division of Infectious Disease, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 18:5-14. 2004
    ..If patients are intolerant of or refractory to conventional therapy, effective alternatives include a lipid formulation of amphotericin B or an echinocandin...
  89. ncbi 5-methylcoumaranones from Mutisia friesiana and their bioactivity
    Carmen I Viturro
    Facultad de Ingenieria, Universidad Nacional de Jujuy, Gorriti 237, 4600 S S de Jujuy, Jujuy, Argentina
    J Nat Prod 67:778-82. 2004
    ..The presence of 5-methylcoumaranones A-D is biosynthetically related to 5-methylcoumarins and phenolic derivatives previously isolated from M. friesiana...
  90. ncbi Short synthesis of the 6,6-spiroketal cores of spirofungins A and B
    Luiz C Dias
    Instituto de Quimica, Universidade Estadual de Campinas, UNICAMP, C P 6154 13084 971, Campinas, SP, Brazil
    Org Lett 6:2587-90. 2004
    reaction: see text] Initial efforts toward the total synthesis of the antifungal antibiotics spirofungins A and B are reported. A short and efficient synthesis of the C9-C20 6,6-spiroketal fragments of both compounds is described...
  91. ncbi The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide)
    Afsaneh Lavasanifar
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta T6G 2N8, Edmonton, Canada
    J Control Release 79:165-72. 2002
    ..The results point to a nanoscopic drug depot that may release AmB at controlled rates...
  92. ncbi [Celso's kerion induced erythema nodosum]
    D Mata Zubillaga
    An Pediatr (Barc) 69:98-9. 2008
  93. ncbi Protection by tetracyclines against ion transport disruption caused by nystatin in human airway epithelial cells
    Y Ito
    Second Division Respiratory Division, First Department of Physiology, School of Medicine, Nagoya University, Tsurumai cho, Nagoya, 466 8550, Japan
    Toxicol Appl Pharmacol 177:232-7. 2001
    Polyene antifungal antibiotics like nystatin form monovalent cation pores on the plasma membrane that perturb the intracellular electrolyte milieu, resulting in cell damage...
  94. doi Treatment of aspergillosis
    Meinolf Karthaus
    Clin Infect Dis 47:427; author reply 427-8. 2008
  95. ncbi Detection of griseofulvin in a marine strain of Penicillium waksmanii by ion trap mass spectrometry
    K E Petit
    SMAB Substances Marines à Activité Biologique, Universite de Nantes, ISOMer, Faculte de Pharmacie, BP 53 508, 44035 Nantes Cedex 01, France
    J Microbiol Methods 58:59-65. 2004
    ..It is the first description of griseofulvin production by a strain of P. waksmanii and the first chemical study of a strain of this species isolated from marine temperate cold water...
  96. ncbi [Rhinocerebral mucormycosis: apropos of 4 new Tunisian cases]
    F Makni
    Laboratoire de Parasitologie-Mycologie, CHU H. Bourguiba, Sfax, Tunisie
    Bull Soc Pathol Exot 94:239-42. 2001
    ..Two patients had a fatal outcome. This infection has a severe prognosis and necessitates early diagnosis...
  97. ncbi Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes
    U Frank
    Institute of Environmental Medicine and Hospital Epidemiology, Freiburg University Hospital, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Eur J Clin Microbiol Infect Dis 23:729-31. 2004
    ..4% and 43.2%, respectively, compared to 37.9% in controls; P<0.05). In conclusion, caspofungin significantly improves oxidative burst and intracellular killing, which may be advantageous for clinical therapy...
  98. ncbi Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects
    Ekatherina Charvalos
    School of Health and Caring Professions, Technological Educational Institution of Athens, Pallikaridou 1, GR 122 10 Aegaleo, Greece
    J Antimicrob Chemother 57:236-44. 2006
    ..Water-soluble complexes of AmB and polyvinylpyrrolidone (AmB-PVP) could display lower cytotoxicity while maintaining antifungal activity...
  99. pmc In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay
    Abdalla O A Ahmed
    Mycetoma Research Group, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Antimicrob Agents Chemother 48:2742-6. 2004
    ..The XTT assay was reproducible and sensitive for both antifungals. Itraconazole (MIC at which 50% of the isolates tested are inhibited [MIC(50)]) of 0.06 to 0.13 mg/liter) was superior to amphotericin B (MIC(50) of 0.5 to 1.0 mg/liter)...
  100. ncbi Candida glabrata infection after total hip arthroplasty
    N Ramamohan
    University Department of Orthopaedic Surgery, Western Infirmary, Glasgow, G11 6NT, UK
    J Infect 42:74-6. 2001
    ..We report successful treatment of a total hip replacement infected with this rare organism by a two-stage revision and synergistic combination antifungal therapy with Amphotericin B and 5-Flucytosine...
  101. ncbi Posaconazole: a new oral antifungal agent with an expanded spectrum of activity
    Michele I Morris
    Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Am J Health Syst Pharm 66:225-36. 2009
    ..The pharmacology, pharmacokinetics, pharmacodynamics, spectrum of activity and resistance, clinical utility, adverse effects, dosage and administration, and recommended monitoring of posaconazole are reviewed...

Research Grants27

  1. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  2. Discovering New Anti-Infective Agents from Lysobacter
    Liangcheng Du; Fiscal Year: 2013
    ..To develop HSAF as a new type of antifungal antibiotics, it is important to understand the biosynthetic mechanism for the novel chemical structure...
  3. GENOMIC SEQUENCING OF CANDIDA ALBICANS
    Ronald Davis; Fiscal Year: 1999
    ..The limited number of effective and safe antifungal antibiotics underscores the importance of increasing our understanding of the unique genetic traits of C. albicans...
  4. ANTISENSE INHIBITION OF FUNGAL GROWTH
    Carol Enderlin; Fiscal Year: 1993
    ..Treatment of fungal infections is difficult due to a lack of effective antifungal antibiotics. Even after 29 years of use, Amphotericin is still the drug of choice to treat systemic fungal infections; ..
  5. Synthesis of Papulacandins A-D; New Antifungal Analogs
    GEORGE O DOHERTY; Fiscal Year: 2005
    ..synthetic/biological investigation of the papulacandins, a class of potent mono-, di-, and trisaccharide antifungal antibiotics. Our study revolves around a unique de novo asymmetric synthetic approach to the papulacandin ring system, ..
  6. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
    ..Furthermore, the genetic construct targeting ATAK cells to Candida can easily be adapted to any other pathogen against which a MAb has been raised. ..
  7. Antifungal Drug Susceptibility of Cryptococcus neoformans
    Robert Larsen; Fiscal Year: 2009
    ....
  8. Transplant Associated Infection Surveillance Network
    Peter Pappas; Fiscal Year: 2008
    ..Finally, the establishment of a bank will be invaluable in the development and validation of newer diagnostic assays. ..
  9. Calcineurin and Aspergillus fumigatus Pathogenesis
    WILLIAM STEINBACH; Fiscal Year: 2008
    ..I will also test the non-immunosuppressive calcineurin inhibitor analogs to decrease the total level of immunosuppression and therefore increase the overall antifungal efficacy of exploiting the calcineurin pathway. ..
  10. Imaging of Pulmonary Cancer: Overcoming Limitations
    Jane Ko; Fiscal Year: 2007
    ..The proposed method will enable early recognition of nodule growth and, therefore, the early diagnosis of malignancy. ..
  11. Epothilone Analogs by Partial Chemical Synthesis
    David Myles; Fiscal Year: 2002
    ..The proposed epothilone analogs with increased solubility will have a potentially competitive advantage for a $2 billion per year market for the treatment of breast, lung and ovarian cancers. ..
  12. ASYMMETRIC SYNTHESIS OF VANCOMYCIN ANTIBIOTICS
    David Evans; Fiscal Year: 2001
    ..During the course of this project we intend to confirm (correct) the absolute stereochemical assignments of the principal members of this family by total synthesis. ..
  13. MELANOGENESIS IN CRYPTOCOCCUS NEOFORMANS
    JOSHUA NOSANCHUK; Fiscal Year: 2002
    ..To explore the structure of melanin using biochemistry, phage display peptide libraries and mAbs; and 4. To use peptides and mAbs to study C. neoformans melanogenesis in vivo and in vitro. ..
  14. ASYMMETRIC SYNTHESIS OF IONOPHORE/MACROLIDE ANTIBIOTICS
    David Evans; Fiscal Year: 2005
    ..Our goal has been to set in place all of the reactions necessary for the rapid assemblage of any polyketide target structure. ..
  15. Clinical Suspicion of TB: A Technology Assessment Tool
    Antonino Catanzaro; Fiscal Year: 2007
    ..It will help define the role of serologic testing in the diagnosis of PTB. ..
  16. EVALUATION OF NIKKOMYCIN Z PHARMACOLOGY FOR TREATMENT OF UNCOMPLICATED COCCIDIODE
    David Nix; Fiscal Year: 2009
    ..By carrying out the proposed work, the investigators will resume the clinical development of nikkomycin Z as a potentially curative therapy for coccidioidomycosis so that it may become a candidate for final commercial development. ..
  17. Antibody Protection in Histoplamosis
    JOSHUA NOSANCHUK; Fiscal Year: 2009
    ..These studies are expected to lead to insights into H. capsulatum pathogenesis and initiate the development of new therapeutic and diagnostic reagents. ..
  18. Genetic Determinants of A. Fumigatus Susceptibility
    Aimee Zaas; Fiscal Year: 2008
    ..fumigatus infection, this proposal will identify and characterize genetic polymorphisms related to IA susceptibility in mice and validate these findings in a cohort of human bone marrow transplant donors and recipients. ..
  19. C. Neoformans Infection in Organ Transplant Recipients
    Nina Singh; Fiscal Year: 2005
    ..Finally, the data regarding reactivation or primary infection has implications relevant for the prevention of C. neoformans infection in transplant recipients. ..
  20. Efficient synthesis of discodermolide
    Gary Ashley; Fiscal Year: 2005
    ..abstract_text> ..
  21. Mobilization of Candida albicans Biofilms
    Peter Suci; Fiscal Year: 2007
    ..albicans biofilm communities, it will provide the basis for development of methods for screening for adjuvant agents that will inhibit dissemination of these fungal infections. [unreadable] [unreadable] [unreadable]..
  22. Synthesis of Polyketides and Terpenes
    David A Evans; Fiscal Year: 2010
    ..As a consequence, organic synthesis is a critical discipline that continues to have an important impact on the fields of both medicine and biology. ..
  23. Motilin Receptor Agonists for Diabetic Gastroperesis
    David Myles; Fiscal Year: 2005
    ....
  24. Fungal transporters: from resistance to new antifungals
    Richard Cannon; Fiscal Year: 2008
    ..This project will increase our understanding of efflux pump structure and function and identify pump inhibitors that could lead to new therapies for patients with opportunistic fungal infections. ..
  25. Prevention/diagnosis/fungal infections/transplantation
    Barbara Alexander; Fiscal Year: 2005
    ..This approach will shorten the time from development to clinical implementation in therapeutic trials and guidelines. ..
  26. Interaction of H. capsulatum with Dendritic Cells
    Simon Newman; Fiscal Year: 2006
    ..The results of these studies should provide significant insight into the pathogenesis of histoplasmosis and aid in the design of novel vaccine strategies for the prevention of disease. ..